- Report
- December 2024
- 68 Pages
Global
From €3770EUR$3,950USD£3,159GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1193EUR$1,250USD£1,000GBP
- Report
- May 2024
- 134 Pages
Global
From €6203EUR$6,499USD£5,197GBP
- Report
- June 2024
- 200 Pages
Global
From €7587EUR$7,950USD£6,357GBP
- Report
- October 2021
- 104 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- August 2022
Global
From €754EUR$790USD£632GBP
- Report
- May 2022
- 38 Pages
Global
From €1909EUR$2,000USD£1,599GBP
The Polymyositis Drug market is a subset of the larger Musculoskeletal Disorders Drugs market. Polymyositis is an inflammatory disorder that affects the muscles, causing muscle weakness and pain. Treatment for this condition typically involves a combination of medications, physical therapy, and lifestyle changes. Common medications used to treat polymyositis include corticosteroids, immunosuppressants, and biologics.
The Polymyositis Drug market is highly competitive, with a number of companies offering products for the treatment of this condition. Companies in this market include AbbVie, Amgen, Biogen, Celgene, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, and Sanofi. These companies are engaged in research and development of new drugs and therapies for the treatment of polymyositis. Show Less Read more
